Annovis Bio, Inc. Common Stock (ANVS)
3.2100
+0.8700 (37.18%)
NYSE · Last Trade: Nov 17th, 1:59 PM EST
Detailed Quote
| Previous Close | 2.340 |
|---|---|
| Open | 2.370 |
| Bid | 3.200 |
| Ask | 3.210 |
| Day's Range | 2.356 - 4.000 |
| 52 Week Range | 1.110 - 7.520 |
| Volume | 37,231,400 |
| Market Cap | 64.80M |
| PE Ratio (TTM) | -3.178 |
| EPS (TTM) | -1.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 464,009 |
Chart
About Annovis Bio, Inc. Common Stock (ANVS)
Annovis Bio Inc is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly conditions like Alzheimer's disease and Parkinson's disease. The company is dedicated to advancing its proprietary platform designed to target and modulate underlying pathologies associated with these diseases. Annovis Bio aims to improve patient outcomes by researching and delivering potential treatments that can enhance cognitive function and overall quality of life for individuals affected by debilitating neurological disorders. Read More
News & Press Releases
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
Via Benzinga · November 17, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · November 17, 2025
Via Benzinga · November 17, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology
Annovis Bio (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a group representing about 25% of the study population. These patients typically experience faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer’s pathology. Annovis noted that the data reinforce its view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson’s and Alzheimer’s disease biology.
Via Investor Brand Network · November 17, 2025
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response
By Annovis Bio Inc. · Via GlobeNewswire · November 17, 2025
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates.
Via Investor Brand Network · November 12, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimer’s study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from its Phase 2/3 Alzheimer’s trial showing strong reductions in inflammation and neurodegeneration, underscoring buntanetap’s disease-modifying potential. Recent achievements include transferring all patents to the new crystal form of buntanetap with IP protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as CFO. “Every element is now aligned as we move toward our data readouts—the final step before an NDA submission,” said Maria Maccecchini, Ph.D., president and CEO.
Via Investor Brand Network · November 12, 2025
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results.
By Annovis Bio Inc. · Via GlobeNewswire · November 12, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. CEO Maria Maccecchini said the study, now 25% complete, reflects strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.
Via Investor Brand Network · November 6, 2025
All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients
By Annovis Bio Inc. · Via GlobeNewswire · November 6, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share, reflecting the Oct. 24 closing price. The $3.4 million offering, led by H.C. Wainwright & Co. as exclusive placement agent, includes participation from Chairman Michael Hoffman and CEO Dr. Maria Maccecchini. Closing is expected on or about Oct. 28, 2025, with proceeds earmarked for working capital and general corporate purposes.
Via Investor Brand Network · October 27, 2025
MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, the Company’s Chief Executive Officer, for the purchase of an aggregate of 1,670,732 shares of its common stock at a purchase price of $2.05 per share, which was the closing price of the common stock on NYSE on October 24, 2025, in a registered direct offering. The closing of the offering is expected to occur on or about October 28, 2025, subject to the satisfaction of customary closing conditions.
By Annovis Bio Inc. · Via GlobeNewswire · October 27, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, closed its previously announced registered direct offering of 4 million shares of common stock (or pre-funded warrants) at $1.50 per share. H.C. Wainwright & Co. served as exclusive placement agent. Gross proceeds totaled approximately $6 million before fees and expenses, with net proceeds intended for working capital and general corporate purposes.
Via Investor Brand Network · October 16, 2025
MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).
By Annovis Bio Inc. · Via GlobeNewswire · October 15, 2025
Via Benzinga · October 10, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · October 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · October 10, 2025
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. The closing of the offering is expected to occur on or about October 13, 2025, subject to the satisfaction of customary closing conditions.
By Annovis Bio Inc. · Via GlobeNewswire · October 10, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Strengthens Neuronal Health in Alzheimer’s Patients
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced new results showing that buntanetap reduced key inflammatory biomarkers and improved neuronal integrity in Alzheimer’s patients. Data from the Phase 2/3 study demonstrated lower levels of IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients versus placebo, along with reduced neurofilament light chain (NFL), suggesting improved cellular health and potential disease-modifying effects. CEO Maria Maccechini said the findings confirm buntanetap’s multi-targeted mechanism and validate earlier preclinical and clinical results, advancing confidence in its potential to deliver meaningful therapeutic benefit.
Via Investor Brand Network · October 9, 2025
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifying effects beyond symptomatic relief.
By Annovis Bio Inc. · Via GlobeNewswire · October 9, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer to help guide the Company as its lead drug candidate, buntanetap, advances through late-stage trials. Guerin previously served as CFO of Onconova Therapeutics, now Traws Pharma (NASDAQ: TRAW), where he oversaw multiple financings and a merger that formed the new entity. His earlier roles include senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand. Guerin said he is eager to support Annovis as it works to replicate buntanetap’s early success in registrational studies and deliver solutions for patients with Alzheimer’s and Parkinson’s disease.
Via Investor Brand Network · September 25, 2025
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development.
By Annovis Bio Inc. · Via GlobeNewswire · September 25, 2025
MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal Biomolecules, which describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across several studies including mice, dogs, and humans.
By Annovis Bio Inc. · Via GlobeNewswire · September 16, 2025
Via Benzinga · September 3, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present at H.C. Wainwright Global Investment Conference
Annovis Bio (NYSE: ANVS) announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8-10, 2025, at the Lotte New York Palace Hotel in New York City.
Via Investor Brand Network · September 2, 2025